W
Wilhelm Gaus
Researcher at University of Ulm
Publications - 67
Citations - 2243
Wilhelm Gaus is an academic researcher from University of Ulm. The author has contributed to research in topics: Placebo & Clinical trial. The author has an hindex of 20, co-authored 67 publications receiving 2160 citations. Previous affiliations of Wilhelm Gaus include Martin Luther University of Halle-Wittenberg.
Papers
More filters
Journal ArticleDOI
Role of octreotide in the prevention of postoperative complications following pancreatic resection.
Markus W. Büchler,Helmut Friess,Istvan Klempa,Peter Hermanek,Udo Sulkowski,Heinz Becker,Anton Schafmayer,Ivo Baca,Lorenz D,Richard Meister,Bernd Kremer,Wagner Pk,J. Witte,Ernst Ludwig Zurmayer,Hans-Detlev Saeger,Bernd Rieck,Peter Dollinger,Karl Glaser,Reinhard Teichmann,Jochen Konradt,Wilhelm Gaus,Hans-Joachim Dennler,Dieter Welzel,Hans G. Beger +23 more
TL;DR: The perioperative application of octreotide reduces the occurrence of typical postoperative complications after pancreatic resection, particularly in patients with tumors.
Journal ArticleDOI
Gabexate mesilate in human acute pancreatitis
Markus W. Büchler,Peter Malfertheiner,W. Uhl,Jürgen Schölmerich,F. Stöckmann,Guido Adler,Wilhelm Gaus,Klaus Rolle,Hans G. Beger +8 more
TL;DR: The results show that gabexate mesilate was not effective in preventing complications and mortality in acute pancreatitis, and the effect of high doses of the low molecular weight protease inhibitor gabExate Mesilate on mortality and complications associated with moderate and severe acute Pancreatitis.
Journal ArticleDOI
Riluzole in Huntington's disease: a 3-year, randomized controlled study.
G. Bernhard Landwehrmeyer,Bruno Dubois,Justo García de Yébenes,Berry Kremer,Wilhelm Gaus,Peter H. Kraus,Horst Przuntek,Michel Dib,Adam Doble,Wilhelm Fischer,Albert C. Ludolph +10 more
TL;DR: A randomized double‐blind trial of riluzole in Huntington's disease finds the efficacy of this antiexcitotoxic drug in slowing disease progression is investigated.
Journal ArticleDOI
Risk factors for alveolar echinococcosis in humans.
Petra Kern,Andrea Ammon,Martina Kron,Gabriele Sinn,Silvia Sander,Lyle R. Petersen,Wilhelm Gaus,Peter Kern +7 more
TL;DR: A case-control study of alveolar echinococcosis cases in Germany identifies several risk factors for the disease.
Journal ArticleDOI
Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial
Achim Jörres,Gerhard M. Gahl,Clemens Dobis,Momir Polenakovic,Koco Cakalaroski,Bolesław Rutkowski,Ewa Kisielnicka,Detlef H. Krieter,K Wolfgang Rumpf,Christian Guenther,Wilhelm Gaus,Josef Hoegel +11 more
TL;DR: There were no differences in outcome for patients with dialysis-dependent acute renal failure between those treated with Cuprophan membranes and those treating with polymethyl-methacrylate membranes, and the main outcome was survival 14 days after the end of therapy.